FDA Clearance Tracker · P140031-S162
Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve Systems
Last checked: Nov 20, 2026Latest source record: May 23, 2024 (this decision)Source: openFDAMethods & limitations
Decided
May 23, 2024
Approved
Time to decision
296 days
Received Aug 1, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P140031-S162
- Device name
- Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve Systems
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Aug 1, 2023
- Decided
- May 23, 2024
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P140031
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
The Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve Systems are indicated for use in patients with symptomatic heart disease due to a failing (stenosed, insufficient, or combined) surgical bioprosthetic mitral valve who are judged by a heart team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >/=4% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.